Core Viewpoint - Achieve Life Sciences Inc. is advancing its cytisinicline drug for nicotine dependence through a partnership with Adare Pharma Solutions for U.S. manufacturing, aiming for a commercial launch in the first half of 2027, while facing challenges that have delayed its timeline from 2026 to 2027 [2][5]. Group 1: Partnership and Manufacturing - The company has partnered with Adare Pharma Solutions to manufacture cytisinicline, which is intended to address nicotine dependence [2]. - This partnership is expected to mitigate risks associated with international importation and potentially lower costs, including tariffs [3]. - The technology transfer to Adare has already commenced [3]. Group 2: Financial Performance - Achieve Life Sciences reported a total net loss of $14.7 million for Q4 2025 and $54.7 million for the full year, with cash and marketable securities amounting to $36.4 million as of December 31, 2025 [4]. Group 3: Regulatory and Clinical Developments - The U.S. FDA inspected a manufacturer related to the cytisinicline application and identified two observations regarding solid oral dose manufacturing, which the company is currently addressing [5]. - New clinical data indicates that cytisinicline shows significant quitting success after 6 and 12 weeks, regardless of prior smoking cessation medication use or previous quit attempts [6]. Group 4: Market Position and ETF Exposure - Cytisinicline is positioned to potentially become the first FDA-approved smoking cessation therapy in nearly 20 years, with a report suggesting it is likely the best therapy for quitting smoking [7]. - Achieve Life Sciences holds a 6.73% weight in the Simplify Propel Opportunities ETF [7]. - The stock price of Achieve Life Sciences was up 0.13% at $2.824 during premarket trading [7].

Company Overview - Achieve Life Sciences, Inc. is a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment for nicotine dependence [7] - Cytisinicline is an investigational product candidate aimed at aiding smoking and e-cigarette cessation by interacting with nicotine receptors in the brain [11] Product Development - Cytisinicline's New Drug Application (NDA) was submitted to the FDA in June 2025 and has been accepted for review, with a Prescription Drug User Fee Act (PDUFA) date set for June 20, 2026 [7] - The NDA is based on two successfully completed Phase 3 studies and an open-label safety study, with a Phase 2 study for vaping cessation also completed [7] Market Need - There have been no new FDA-approved treatments for smoking cessation in 20 years, and no FDA-approved treatments for vaping cessation, highlighting a significant market opportunity [2] - Approximately 25 million U.S. adults smoke, and nearly 18 million vape, with more than half of these individuals wanting to quit [2] Clinical Findings - Recent findings indicate that cytisinicline binds strongly to the α4β2 nicotinic receptor, displacing nearly all (99%) of a comparison compound, suggesting effective targeting for smoking cessation [8] - Cytisinicline shows minimal interaction with the 5-HT3 serotonin receptor (-8% displacement), which is significant as this receptor's activation is linked to nausea, thus explaining cytisinicline's favorable tolerability profile [8][3] Safety and Efficacy - Clinical studies have reported low rates of adverse events like nausea associated with cytisinicline, supporting its potential as a more tolerable option for individuals attempting to quit smoking [5][3] - Participants in a long-term safety study self-reported high quit and reduction rates of nicotine use, driven by fewer cravings and manageable side effects [5]

Strategic Transformation and Operational Context - Achieve Life Sciences has transitioned from a clinical development firm to a commercially focused enterprise following the June 2025 NDA submission for cytisinicline [5] - The ORCA-OL study demonstrated safety and tolerability over 52 weeks, addressing long-term treatment concerns and attributed strong clinical momentum [5] - A significant market opportunity has been identified among the 6 million COPD smokers in the U.S., with post-hoc data showing cytisinicline significantly improved quit rates [5] Launch Strategy and Regulatory Outlook - The company has pivoted to a lean, omnichannel commercial model, recognizing that 75% of primary care physicians no longer meet with traditional medical representatives [5] - Anticipated commercial launch is set for the first half of 2027, allowing time for manufacturing scale-up and establishing a robust U.S. supply chain [5] - The company is leveraging the Commissioner's National Priority Voucher to expedite the vaping cessation indication, targeting a review timeline of 1 to 2 months [5] Supply Chain and Risk Factors - Strategic selection of Adare Pharma Solutions for U.S. manufacturing aims to secure the supply chain and mitigate risks from international tariffs and importation uncertainties [5] - The company maintains a strategic stockpile of raw starting material sufficient for more than 3 years of market demand to ensure long-term supply continuity [5] - Two FDA GMP inspection observations at the current NDA-named manufacturer have prompted an accelerated technology transfer to Adare Pharma Solutions [5] Q&A Session Highlights - There is a noted gap between the June approval and the H1 2027 launch timing, with a focus on ensuring supply reliability through U.S.-based manufacturing [6][7] - The geopolitical rationale for onshoring manufacturing to the U.S. is highlighted to provide redundancy and contingency capacity [7]

Financial Data and Key Metrics Changes - As of December 31, 2025, cash equivalents and marketable securities totaled $36.4 million [25] - Total operating expenses for Q4 2025 were $14.7 million, and for the full year, they were $54.9 million, reflecting ongoing investments in regulatory, clinical, and commercial activities [25] - The total net loss for Q4 2025 was $14.7 million, and for the full year, it was $54.7 million [25] Business Line Data and Key Metrics Changes - Achieve Life Sciences is transitioning from a clinical development company to a commercially focused enterprise, with a primary objective to make cytisinicline available to 25 million smokers and nearly 18 million vapers [5][6] - The NDA submission for smoking cessation was accepted by the FDA, marking a significant step towards becoming the first new FDA-approved treatment in 20 years [6][7] - The ORCA-OL long-term exposure trial demonstrated cytisinicline's safety profile, showing strong tolerability and excellent patient satisfaction [8] Market Data and Key Metrics Changes - Approximately 25 million adults in the U.S. smoke cigarettes, with over 15 million attempting to quit each year [12] - The CDC estimates that smoking causes around 500,000 deaths annually and incurs over $600 billion in healthcare costs and lost productivity [12] - There are 6 million COPD smokers in the U.S. with limited options for cessation, highlighting the potential market for cytisinicline [8] Company Strategy and Development Direction - The company aims to launch cytisinicline for smoking cessation in the first half of 2027, focusing on ensuring supply chain readiness and building a scalable commercial model [9][10][19] - Achieve is leveraging AI and advanced analytics to enhance decision-making and customer engagement, positioning itself for an efficient launch [10][23] - The company has initiated a "Willpower" awareness campaign to reframe the conversation around nicotine dependence as a medical condition [14][22] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the regulatory progress and the potential for cytisinicline to deliver the first FDA-approved treatment for nicotine dependence in two decades [18] - The company is focused on addressing the unmet medical needs in nicotine dependence, emphasizing the importance of a controlled and successful product launch [26][27] - Management highlighted the urgency of the public health need for vaping cessation treatments, with the potential to be first to market [27] Other Important Information - Achieve has partnered with Adare Pharma Solutions for U.S. manufacturing, which is expected to enhance supply chain security and reduce risks associated with international imports [10][11] - The company is actively engaging with payers to secure coverage and affordability for cytisinicline, with ongoing discussions showing positive feedback [21][53] Q&A Session Summary Question: What is the critical path between NDA approval and launch? - The company needs to ensure drug availability in the supply chain and is working on additional data and partnerships during the lead-up to launch [30][31] Question: Will the manufacturer in the NDA supply commercial product? - The company plans to transfer manufacturing to Adare, ensuring contingency supply and addressing observations from the FDA inspection [36][37] Question: What is the current awareness level among healthcare providers? - Awareness has not been a priority pre-approval, but the company plans to ramp up educational efforts as the launch approaches [40][42] Question: What is the status of FDA dialogue on the vaping indication? - Discussions with the FDA have focused on protocol approval, with site selection for the ORCA-V2 trial already underway [44][45] Question: How robust is the raw plant material supply chain? - The company has stockpiled sufficient starting material for over three years of supply, ensuring readiness for market demand [58] Question: What are the pricing considerations for cytisinicline? - The company is not ready to comment on pricing but acknowledges the substantial unmet need highlighted in the ICER report [66][68]

Financial Data and Key Metrics Changes - As of December 31, 2025, cash equivalents and marketable securities totaled $36.4 million, with total operating expenses for Q4 2025 at $14.7 million and for the full year at $54.9 million, reflecting ongoing investments in regulatory, clinical, and commercial activities [25] - The total net loss for Q4 2025 was $14.7 million and for the full year was $54.7 million, indicating a consistent investment strategy despite losses [25] Business Line Data and Key Metrics Changes - Achieve Life Sciences is transitioning from a clinical development company to a commercially focused enterprise, with a primary objective to make cytisinicline available to 25 million smokers and nearly 18 million vapers in the U.S. [5][6] - The NDA submission for smoking cessation was accepted by the FDA, marking a significant milestone towards becoming the first new FDA-approved treatment in 20 years [6][7] Market Data and Key Metrics Changes - The company highlighted the urgent public health need for nicotine dependence treatment, with approximately 25 million adults in the U.S. smoking and over 15 million attempting to quit annually [12] - The recognition of cytisinicline as a national priority by the FDA enhances its market potential, particularly for vaping cessation, where no approved treatments currently exist [6][18] Company Strategy and Development Direction - Achieve is building a scalable, data-driven commercial model to launch cytisinicline, utilizing an omni-channel digital platform for precision targeting of physicians and patients [9][10] - The partnership with Adare Pharma Solutions aims to secure the supply chain and reduce risks associated with international pharmaceutical importation, enhancing operational readiness for the planned commercial launch in the first half of 2027 [10][11] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the regulatory progress and the potential of cytisinicline to deliver the first FDA-approved treatment for nicotine dependence in two decades, emphasizing the importance of addressing the unmet medical needs in this area [26][27] - The company is focused on ensuring a controlled and successful launch, with ongoing discussions with payers to secure coverage and affordability for cytisinicline [19][53] Other Important Information - The ORCA-OL long-term exposure trial demonstrated cytisinicline's safety profile and strong tolerability, with high patient satisfaction reported [8][17] - The company is leveraging advanced analytics and machine learning to enhance decision-making and customer engagement, positioning itself for an efficient launch [9][23] Q&A Session Summary Question: Can you talk about the critical path between a late June NDA approval and a first half launch? - The primary consideration is ensuring drug availability in the supply chain, with all trade and distribution processes ready to go once the drug is available [30][31] Question: Did you imply that the manufacturer in the NDA will not be supplying commercial product, rather Adare will? - The PDUFA date remains June 20, and the decision to transfer manufacturing to the U.S. was made to ensure contingency supply and address geopolitical concerns [36][37] Question: Can you discuss the current awareness level with healthcare providers and plans for 2026? - Awareness has not been a priority yet, but as the launch approaches, the company plans to ramp up educational efforts specific to cytisinicline [40][42] Question: What is the status of the raw plant material supply chain? - The company has been stockpiling starting material and expects to have more than three years' supply by the time of launch [58] Question: Can you comment on the cytisinicline dosing schedule and potential compliance issues? - High adherence rates were reported in trials, with participants finding the dosing schedule manageable and effective in addressing cravings [60][61] Question: What are the pricing considerations for cytisinicline? - The company is not ready to comment on pricing but acknowledges the substantial unmet need highlighted in the ICER report [66][68]

Financial Data and Key Metrics Changes - As of December 31, 2025, cash equivalents and marketable securities totaled $36.4 million [22] - Total operating expenses for Q4 2025 were $14.7 million, and for the full year, they were $54.9 million, reflecting ongoing investments in regulatory, clinical, and commercial activities [22] - The total net loss for Q4 2025 was $14.7 million, and for the full year, it was $54.7 million [22] Business Line Data and Key Metrics Changes - The NDA submission in June 2025 marked a transition for the company from clinical development to a commercially focused enterprise [4] - The company aims to make cytisinicline available to 25 million smokers and nearly 18 million vapers in the U.S. [4] - The ORCA-OL long-term exposure trial demonstrated cytisinicline's safety profile, showing strong tolerability and excellent patient satisfaction [6] Market Data and Key Metrics Changes - Approximately 25 million adults in the U.S. smoked cigarettes in 2024, with over 15 million attempting to quit annually [10] - There are 6 million COPD smokers in the U.S. with limited options to help them quit, highlighting the need for effective treatments [6] Company Strategy and Development Direction - The company is focused on launching cytisinicline as the first FDA-approved treatment for nicotine dependence in 20 years [5] - Achieve Life Sciences is building a scalable, data-driven commercial model to effectively target physicians and patients [7] - The partnership with Adare Pharma Solutions aims to secure the supply chain and reduce risks associated with international pharmaceutical importation [8] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the regulatory progress and the potential for cytisinicline to deliver a new treatment option for nicotine dependence [16] - The company is committed to addressing the public health crisis of nicotine dependence and is actively building for the product launch [24] - The management emphasized the importance of a controlled and successful launch, ensuring all processes are in place [32] Other Important Information - The company received the FDA Commissioner's National Priority Voucher for vaping cessation, which provides an expedited review timeline [16] - The Willpower awareness campaign was launched to reframe the conversation around nicotine dependence as a medical condition [11] Q&A Session Summary Question: Can you talk about the critical path between a late June NDA approval and a first half launch? - The company needs to ensure drug availability in the supply chain before market entry, with all trade and distribution processes ready upon drug availability [27][28] Question: Did you imply that the manufacturer in the NDA will not be supplying commercial product, rather Adare will? - The company confirmed that the PDUFA date remains unchanged, and the decision to transfer manufacturing to the U.S. was made to ensure supply chain security [33] Question: Can you talk about healthcare provider awareness and additional work in 2026? - The company has been conservative in spreading awareness prior to product availability but plans to ramp up educational efforts as the launch approaches [38] Question: What is the status of the FDA dialogue on the vaping indication since receiving the CMPV? - Discussions with the FDA have focused on protocol approval, with site selection for the ORCA-V2 phase III trial already underway [40][41] Question: How robust is the raw plant material supply chain? - The company has been stockpiling starting material and expects to have more than three years' supply by the time of launch [56] Question: What is the cytisinicline dosing schedule and potential compliance concerns? - High adherence rates were reported in trials, with participants finding the dosing schedule manageable and effective in addressing cravings [58][59] Question: What are the pricing considerations for cytisinicline? - The company is not ready to comment on pricing but acknowledges the substantial unmet need highlighted in the ICER report [62][65]

Core Viewpoint - Achieve Life Sciences, Inc. is set to report its fourth quarter and full year 2025 financial results on March 24, 2026, alongside updates on the cytisinicline development program [1] Company Overview - Achieve Life Sciences, Inc. is a late-stage specialty pharmaceutical company focused on developing and commercializing cytisinicline for nicotine dependence treatment [3] - The company submitted a New Drug Application (NDA) to the FDA in June 2025, which has been accepted for review, with a PDUFA date set for June 20, 2026 [3] - Cytisinicline is intended for smoking cessation in adults, supported by two completed Phase 3 studies and an open-label safety study [3] Industry Context - Approximately 25 million adults in the U.S. smoke combustible cigarettes, with tobacco use being the leading cause of preventable death, resulting in over 8 million deaths globally and nearly 500,000 in the U.S. annually [4] - There are nearly 18 million adults in the U.S. who use e-cigarettes, with no FDA-approved treatments specifically for e-cigarette cessation [5] - The FDA has recognized the need for e-cigarette cessation treatments by awarding a National Priority Voucher and granting Breakthrough Therapy designation [5] Product Information - Cytisinicline is a plant-based alkaloid that binds to nicotinic acetylcholine receptors, potentially aiding in nicotine addiction treatment by reducing cravings and satisfaction associated with nicotine [6] - The product is still investigational and has not yet received FDA approval for any indication in the U.S. [6]

Core Insights - Achieve Life Sciences, Inc. announced new data indicating that cytisinicline is effective in helping individuals quit smoking, including those who have previously failed with other cessation medications and regardless of their quit attempt history [1][4][3] Group 1: Clinical Data and Efficacy - A pooled Phase 3 analysis involving over 1,600 participants demonstrated high quit rates with cytisinicline after 6 and 12 weeks of treatment, showing effectiveness across various prior treatment histories [1][3] - The analysis included participants with different backgrounds, such as those who had used varenicline, bupropion, and nicotine replacement therapy, and categorized them based on their number of previous quit attempts [3][4] - Cytisinicline was shown to benefit individuals regardless of their prior quit history, providing hope for those who have faced setbacks in their attempts to quit smoking [4][3] Group 2: Patient Experience and Safety - Late-breaking survey data from the ORCA-OL study highlighted participant experiences with extended use of cytisinicline, contributing to a comprehensive understanding of its impact on quitting smoking [2][4] - Participants reported meaningful benefits from cytisinicline, including successful quitting and improvements in physical health, emphasizing the importance of patient experience in smoking cessation efforts [5][4] Group 3: Regulatory and Market Context - Achieve Life Sciences is focused on the global development and commercialization of cytisinicline for nicotine dependence, with a New Drug Application submitted to the FDA that is currently under review [7] - The FDA has set a Prescription Drug User Fee Act (PDUFA) date of June 20, 2026, for the cytisinicline application, which is based on successful Phase 3 studies and an open-label safety study [7] - The company has also completed a Phase 2 study for vaping cessation, indicating a broader strategy to address nicotine dependence beyond traditional smoking [7]

Core Viewpoint - Achieve Life Sciences has promoted Dr. Mark Rubinstein to Chief Medical Officer following his successful tenure as Interim CMO, during which the company achieved significant clinical and regulatory milestones in the development of cytisinicline for smoking cessation [1][2][3]. Company Overview - Achieve Life Sciences, Inc. is a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment for nicotine dependence [5]. - The company submitted a New Drug Application (NDA) to the FDA in June 2025, which has been accepted for review, with a Prescription Drug User Fee Act (PDUFA) date set for June 20, 2026 [5]. Clinical Development - Under Dr. Rubinstein's leadership, Achieve Life Sciences has co-authored a paper demonstrating the efficacy and tolerability of cytisinicline for smoking cessation in individuals with Chronic Obstructive Pulmonary Disease (COPD) [2]. - Cytisinicline has shown a robust safety profile in long-term trials, indicating its potential to address unmet medical needs related to nicotine dependence [4]. Market Context - Approximately 29 million adults in the U.S. smoke combustible cigarettes, with tobacco use being the leading cause of preventable death, responsible for over 8 million deaths globally and nearly half a million in the U.S. annually [6]. - There are around 17 million adults in the U.S. who use e-cigarettes, with no FDA-approved treatments specifically for nicotine e-cigarette cessation [7]. Product Mechanism - Cytisinicline is a plant-based alkaloid that interacts with nicotinic acetylcholine receptors in the brain, helping to reduce nicotine cravings and the satisfaction associated with nicotine products [8].

Core Insights - Achieve Life Sciences, Inc. has received FDA acceptance for its New Drug Application (NDA) for cytisinicline, targeting a Prescription Drug User Fee Act (PDUFA) action date of June 20, 2026, for smoking cessation treatment [2][5][13] - The FDA awarded cytisinicline the Commissioner's National Priority Voucher for vaping cessation, highlighting its potential as the first FDA-approved therapy for nicotine dependence related to vaping [2][7][15] - Recent post hoc data published in Thorax indicates that cytisinicline significantly improves smoking quit rates in adults with chronic obstructive pulmonary disease (COPD) [4][8] Company Developments - Achieve Life Sciences has made significant advancements in its cytisinicline development program, including the completion of key clinical trials and safety updates [4][9] - The company appointed Erik Atkisson as Chief Legal Officer, enhancing its leadership team as it prepares for regulatory review and potential commercialization [10] - Financial results as of September 30, 2025, show cash and cash equivalents of $48.1 million, with total operating expenses of $14.7 million for the third quarter [11][21] Market Context - Approximately 60% of the 17 million adult e-cigarette users in the U.S. express a desire to quit, indicating a significant unmet medical need for effective cessation therapies [2][15] - Cytisinicline is positioned as a potential first-in-class treatment for vaping cessation, addressing a growing public health concern [7][15] - The tobacco use landscape includes around 29 million adults in the U.S. who smoke combustible cigarettes, with tobacco being the leading cause of preventable death [14][15]